Giannelli et al. performed a study on 40 patients diagnosed with HCC, in which serum and tumor tissue levels of MMP-2 and TIMP-2 were measured at the time of diagnosis, and the clinical outcome was then followed over a two-year period. This evidence concerns the gene TIMP2 and hepatocellular carcinoma.